Market Overview

Glaxo, Theravance Confirm BREO ELLIPTA Gained US FDA Approval for Treatment of COPD

Share:
Related GSK
Benzinga's Volume Movers
5 NYSE Healthcare Stocks With The Highest ROE
Corruption allegations bubble up again for Glaxo, this time in Romania (Seeking Alpha)
Related THRX
Short-Sellers Betting Against These Biotechs
Morning Market Losers
Theravance declares $0.25 dividend (Seeking Alpha)

GlaxoSmithKline plc (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved BREO(TM) ELLIPTA(TM) as an inhaled long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. It is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations. BREO ELLIPTA is a combination of the inhaled corticosteroid (ICS), fluticasone furoate "FF", and the long-acting beta2 agonist (LABA), vilanterol "VI" (FF/VI 100/25 mcg).

Posted-In: News FDA

 

Related Articles (THRX + GSK)

Get Benzinga's Newsletters